Legend Biotech director sells 6,000 shares

Legend Biotech Corp director Casey Patrick John sold 6,000 Ordinary Shares in an open-market transaction.

Rhea-AI Filing Summary

Legend Biotech Corp director Casey Patrick John sold 6,000 Ordinary Shares in an open-market transaction. The sale took place at $14.80 per ordinary share, equivalent to $29.60 per American Depositary Share, with each ADS representing two ordinary shares. After this trade, he directly holds 48,604 Ordinary Shares, indicating he retains a substantial ongoing equity position in the company.

Insider Trade Summary

Net Seller: 6,000 shares

Net Sell 1 txn

Insider Casey Patrick John

Role Director

Sold 6,000 shs ($89K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	6,000	$14.80	$89K

Holdings After Transaction: Ordinary Shares — 48,604 shares (Direct)

Footnotes (2)

1. F1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.
2. F2. The price reported in Column 4 represents the converted sales price of ADSs of $29.60 per ADS (which is equivalent to $14.80 per ordinary share).

Key Figures

Shares sold: 6,000 shares Sale price per ordinary share: $14.80 per share Sale price per ADS: $29.60 per ADS +2 more

5 metrics

Shares sold 6,000 shares Ordinary Shares sold on 2026-06-30 in open-market transaction

Sale price per ordinary share $14.80 per share Converted from $29.60 per ADS

Sale price per ADS $29.60 per ADS Each ADS represents two Ordinary Shares

Shares held after transaction 48,604 shares Total Ordinary Shares directly owned following sale

Net shares sold 6,000 shares Net-sell direction per transaction summary

Key Terms

American Depositary Shares, ADSs, open-market sale, Ordinary Shares

4 terms

American Depositary Shares financial

"The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs")."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

ADSs financial

"Each ADS represents two ordinary shares of the Issuer."

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

"The Ordinary Shares of the Issuer may be represented by American Depositary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Legend Biotech (LEGN) report for Casey Patrick John?

Legend Biotech reported that director Casey Patrick John sold 6,000 Ordinary Shares in an open-market transaction. The shares were sold at $14.80 per ordinary share, and he continues to hold 48,604 Ordinary Shares directly after the sale.

At what price were the Legend Biotech (LEGN) shares sold in this Form 4 filing?

The shares were sold at $14.80 per ordinary share, which corresponds to $29.60 per American Depositary Share. Each ADS represents two ordinary shares, so the filing provides both values to align with how the stock trades in U.S. markets.

How many Legend Biotech (LEGN) shares does Casey Patrick John hold after the sale?

After selling 6,000 Ordinary Shares, Casey Patrick John holds 48,604 Ordinary Shares directly. This indicates that the transaction reduced, but did not eliminate, his stake, and he continues to maintain a meaningful equity interest in Legend Biotech.

How are Legend Biotech (LEGN) Ordinary Shares related to its American Depositary Shares (ADSs)?

Each Legend Biotech American Depositary Share represents two Ordinary Shares of the company. The filing notes that the $29.60 per ADS sale price is equivalent to $14.80 per ordinary share, clarifying the conversion for investors tracking ADS prices.

What does the Form 4 transaction code 'S' mean in the Legend Biotech (LEGN) filing?

In this Form 4, transaction code "S" indicates an open-market or private sale of securities. The filing specifies this as an open-market sale of 6,000 Ordinary Shares by director Casey Patrick John at a price of $14.80 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Casey Patrick John

(Last) (First) (Middle)

C/O LEGEND BIOTECH CORP

2101 COTTONTAIL LANE

(Street)

SOMERSET NEW JERSEY 08873

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Legend Biotech Corp [ LEGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/30/2026		S		6,000	D	$14.8(2)	48,604	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

2. The price reported in Column 4 represents the converted sales price of ADSs of $29.60 per ADS (which is equivalent to $14.80 per ordinary share).

	/s/ James Pepin, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)